Larson Financial Group LLC bought a new stake in shares of SIGA Technologies, Inc. (NASDAQ:SIGA – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,400 shares of the company’s stock, valued at approximately $30,000.
Several other large investors have also recently made changes to their positions in the business. DekaBank Deutsche Girozentrale purchased a new stake in shares of SIGA Technologies in the 2nd quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in SIGA Technologies by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,727 shares of the company’s stock worth $93,000 after acquiring an additional 5,372 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of SIGA Technologies in the second quarter worth $99,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of SIGA Technologies by 38.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock valued at $104,000 after acquiring an additional 3,829 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of SIGA Technologies during the first quarter valued at $105,000. 55.40% of the stock is currently owned by hedge funds and other institutional investors.
SIGA Technologies Price Performance
Shares of SIGA Technologies stock opened at $7.28 on Friday. SIGA Technologies, Inc. has a 1 year low of $4.26 and a 1 year high of $12.83. The firm’s 50-day moving average is $6.94 and its 200 day moving average is $7.85. The stock has a market cap of $519.79 million, a price-to-earnings ratio of 6.07 and a beta of 0.89.
SIGA Technologies Company Profile
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Recommended Stories
- Five stocks we like better than SIGA Technologies
- Retail Stocks Investing, Explained
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Investing in the High PE Growth Stocks
- MarketBeat Week in Review – 11/25 – 11/29
- What is the Shanghai Stock Exchange Composite Index?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.